lifestyle.careersavvy.co.uk

Author: Knight Therapeutics

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2026
Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

March 27, 2026
Knight Amends Normal Course Issuer Bid

March 23, 2026
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

March 19, 2026
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

March 17, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call

March 12, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 20, 2026